79 results about "Cervical cancer screening" patented technology

The invention relates to a cervical exfoliated cell preservative liquid, the preservative liquid comprises the following components with the contents (by weight): 20 percent to 50 percent of alcohols; 15 percent to 50 percent of anti-aggregation reagent; 5 percent to 10 percent of buffer solution; 1 percent to 20 percent of ion strength maintaining reagent; 0.01 percent to 0.5 percent of anti-microbial reagent; 0.1 to 5 percent of mucus dissolving reagent; and 0 to 0.5 percent of cleaning agent. Compared with the prior art, the preservative liquid can not only lead cells to maintain the shape in an in vitro liquid suspension environment, minimize the protein precipitation, dissolve larger protein substances, such as blood and mucus, and reduce the cell aggregation, but can also selectively eliminate or reduce red cells, effectively kill microbes, prevent the activity of reverse transcriptase and retain the integrity of nucleic acids and proteins for facilitating the later analysis; in addition, the preservative liquid can greatly reduce the costs of consumptive materials for the TCT detection, improve the sensitivity and the specificity of the cervical cancer screening and accelerate the promotion and the popularization of the TCT technology in a medical system.

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

Cervical Acid Phosphatase-Papanicolaou Test Kit (CPK) is an assembly of reagents, controls and instructions for visualization of cervical acid phosphatase on smears or monolayers of cervical specimens, and for performing the CAP-PAP Test (CPT). CPT is a single-slide, double-staining method for demonstration of cervical acid phosphatase activity inside abnormal cervical cells on Papanicolaou stained smears, and a set of criteria for using this test for cervical cancer screening. In previous clinical trials this method was found to enable Pap test screeners to improve test sensitivity (detection of abnormal cells) for more than 10% (from 0.8 to 0.9), and to reduce false negative readings (missing abnormal cells) for more than 50% (from 0.1 to 0.02). Due to better accuracy and the low cost, when approved, CPT may begin to replace current technologies for cervical cancer screening. CPK is designed to meet requirements for testing large series of specimens on regular basis-the usual practice in cytopathology laboratories performing the Pap test. CPK brings consistency for staining and interpretation, makes internal and external controls easier, and improves the test accuracy for lower cost, while increases laboratory productivity for less liability.

The present invention relates to an apparatus for cervical cancer screening, comprising one or more light sources aligned with a beginning of a first optical test path and a beginning of a second optical test path, one or more optical detectors aligned with an end of the first optical test path and an end of the second optical test path, and a processor coupled to the one or more light sources and the one or more optical detectors and methods for using the same. The present invention further relates to a method for cervical cancer screening.

A method and apparatus for personal screening for early signs of cervical cancer is claimed, whereby the user performs daily or almost daily a diagnostic self-check for some other aspect of reproductive health, and the electronic testing for cervical cancer type of tissue aberration is performed automatically in the background. The screening is invisible to the user, causing no anxiety and no discomfort. The user only becomes alerted to the need to see a physician if a preset condition of reproducibility is reached in the background evaluation of the measurement data if the aberrant pattern has been detected consecutively in a preset number of menstrual cycles, the device prompts the woman to see a physician with a view to undergoing a more demanding definitive diagnostic examination such as colposcopy with biopsy. The invention provides the diagnostic screen in a manner that does not cause the discomfort, anguish and anxiety associated with the Pap smear screen of the prior art.

The invention discloses a cervical cancer cell detection kit based on a boron-doped graphene quantum dot and belongs to the field of biological detection. The cervical cancer cell detection kit comprises reagents A, B and C. The reagent A is a boron-doped graphene quantum dot solution, the reagent B is a cerium nitrate solution, and the reagent C is an adenosine triphosphate solution. Alkaline phosphatase is selected for the kit to serve as a detected targeted goal, the boron-doped graphene quantum dot is adopted as a fluorescent probe, alkaline phosphatase on the surfaces of cervical cancer cells is detected quickly and efficiently through a quantum dot fluorescence analysis method, and the kit can be used in the medical field to detect the cervical cancer cells and concentration thereof. The kit has the advantages of being easy to operate, high in detection result accuracy and sensitivity and low in cost and the like.

The invention discloses a clinical decision-making system and method for cervical lesions. The clinical decision-making system comprises: a terminal acquisition module for acquiring case data of a patient; an input conversion module for extracting the case data of the patient and converting into characteristic variables; a data processing module for respectively performing discretization, sparse coding and binarization processing on the characteristic variables; a prediction module for outputting prediction results after the processed characteristic variables are subjected to weight and offsetdimension assignment processing, rectification function relu transformation and softmax regression operation; a conformation and diagnosis module for confirming final clinical diagnosis results and providing true labels for the prediction results; a data center module for receiving and storing all case data of the patient and periodically iterating the prediction module based on all data; and a display module for displaying the prediction results, the diagnosis results and health guidance advice. The clinical decision-making system and method provided by the invention can improve specificityand accuracy of a current cervical cancer screening strategy, and realize big data sharing and integrated network management of cervical cancer screening.

An apparatus and method are provided for sampling the distal tube, fimbria and/or ovary, includes advancing a device into the peritoneal cavity and sampling material on or adjacent to the distal tube, fimbria or ovary.

The invention provides a cervical cancer section recognition method which comprises the following steps of performing the pre-training to form a cervical cancer recognition model according to the pre-prepared training sample associated with a cervical cancer section; and further comprises the following steps of acquiring a pathological section image to be recognized; recognizing the pathological section image through the cervical cancer recognition model, and outputting the recognition result, wherein the recognition result comprises the number of the cervical cancer cells in the pathologicalsection image and the positions of the cervical cancer cells in the pathological section image. The method has the beneficial effects that the suspected cervical cancer cells in the cervical cancer image can be quickly positioned, redundant information is effectively reduced, and the workload in the recognition process is reduced; the digital cervical cancer image can be subjected to statistics instead of a traditional artificial visual mode, the artificial diagnosis process is assisted, and the artificial diagnosis efficiency is greatly improved.

The invention belongs to the technical field of clinical medicine, provides application of Notch1, p16<INK4a> and hTERC genes as screening markers for cervical cancer, and relates to molecular markersfor detecting double or triple genes of cervical precancerous lesion and early diagnosis of the cervical cancer. Patients with cervical disease have no significant symptoms in the early stages of onset, and are easily overlooked and fail to be treated in time, so that the risk of the disease and the difficulty of treatment are increased. It is controversial to use p16<INK4a> protein as a diagnostic screening index for the cervical cancer, and the credibility is not high. The invention provides a set of markers, namely, the application of the Notch1, p16<INK4a> and hTERC genes as the screeningmarkers for the cervical cancer, positive correlation exists between p16<INK4a>, Notch1 and hTERC genes and carcinogenesis of HPV16, and significant positive correlation exists between p16<INK4a> andhTERC genes and the carcinogenesis of the HPV16, and the markers can be used for application of molecular marker reagents for detecting double or triple genes of cervical precancerous lesion and early diagnosis or screening of the cervical cancer.

An artificial intelligence cervical cancer screening system includes at least one user terminal, at least one intelligent hardware detection trolley, at least one hospital terminal, an intelligent management terminal and a data cloud center, the at least one user terminal, at least one intelligent hardware detection platform The car, at least one hospital terminal and the intelligent management terminal are all networked and connected to the data cloud center through the network. The system has high efficiency in seeing a doctor. Patients can make appointments for various examinations and seeing a doctor through the user terminal, which shortens the efficiency of seeing a doctor and saves waiting time for patients. Moreover, this system realizes the sharing and query of all data, which facilitates the patient's experience in seeing a doctor, and also provides patient data for statistical management by the superior health management department.

The invention discloses a cervical cancer screening kit, comprising an optional reagent to detect expression level of SPARCL1 in blood. The invention also discloses the application of the reagent to detect the expression level of SPARCL1 in blood, in the preparation of cervical cancer screening reagents. The cervical cancer screening kit can effectively judge the risk of people under test to suffer cercal cancer by detecting the expression level of SPARCL1, is applicable to the clinical assisted diagnosis of cervical cancer, provides effective basis for taking related treatment measures or making decisions for patients, and has a good clinical application prospect.

Point-of-care tools for screening biological samples for markers associated with pathogenic microbial infections. In particular, devices and systems for screening cervical cells for the expression of proteins, which occur as a result of human papillomavirus infection and progression to invasive cervical cancer.

The invention discloses a method for ovarian cancer screening based on an ovarian cancer marker and a logic gate operation, and belongs to the technical field of biomedicine. The protein-nucleic acidrecognition technology, the signal amplification technology and a logic gate are combined, aptamers of CEA and CA125 are used for target recognition, signal transformation and amplification are performed through a G-quadruplex-heme complex, and a method for simultaneous detection of tumor markers is established. According to the method, an optical biosensor with high sensitivity and strong specificity is constructed for achieving the joint detection of the CEA and the CA125, and an ovarian cancer screening result is provided based on the logic gate; through the combination of optical detectionand the signal amplification technology, the detection sensitivity is improved; the universality of the detection principle makes the method also suitable for detection of different objects based ondifferent protein recognition elements.

The invention belongs to the technical field of immunology, and particularly relates to a household cervical cancer screening reagent card which comprises a bottom plate, a sample pad, a latex combination pad, a nitrocellulose membrane and an absorption pad, detection lines and a quality control line are arranged on the nitrocellulose membrane, the detection lines comprise a p16 detection line and a ki-67 detection line, and the quality control line comprises a quality control line and a quality control line. The p16 detection line, the ki-67 detection line and the quality control line are parallel to one another, and the p16 detection line and the ki-67 detection line are respectively obtained by spraying a solution of a p16-point membrane antibody and a solution of a ki-67-point membrane antibody on the nitrocellulose membrane. According to the household cervical cancer screening reagent card, the p16 point membrane antibody and the ki-67 point membrane antibody are adopted to obtain the p16 detection line and the ki-67 detection line respectively, detection results of the two detection lines are combined and analyzed, various physical conditions can be evaluated, the detection accuracy is improved, in addition, the reagent card is simple in using method, and the results are simple and easy to understand.

The invention belongs to the technical field of medical devices, and discloses a cervical lesion detector which comprises a pressure power device and a detection bar. The pressure power device comprises a holding body, a base hole is formed in the front end of the holding body, a transmission sleeve is arranged in the base hole and rotates relative to the base hole, a wireless pressure sensor is arranged at the bottom of the transmission sleeve, a motor and a main board are arranged in the holding body, the motor is used for driving the transmission sleeve, the main board is used for controlling the motor to run, the detection bar comprises a detection shaft matched with the transmission sleeve, a conical detection head is arranged at the front end of the detection shaft, the rear end of the detection shaft can be inserted into a sleeve, and the pressure is applied to the wireless pressure sensor. According to the detector, a clinician can independently judge and read a result in cervical lesions detection, and the detector is bedside, easy to operate, low in cost, short in time and suitable for popularization and use and solves awkward situations in domestic cervical cancer screening of women.

The invention discloses a primer combination, a probe combination and a human papilloma virus nucleic acid detection kit. The invention relates to the field of biological detection, in particular to aPCR fluorescent probe detection method for diagnosing high-risk human papilloma virus infection, which comprises the following steps: extracting human papilloma virus nucleic acid in cervical exfoliated cells by using a paramagnetic particle method, and carrying out real-time fluorescence polymerase chain reaction to obtain the high-risk human papilloma virus detection kit to detect 14 HPV DNA types in the sample and typing the HPV 16/18; and meanwhile, carrying out female cervical cancer screening in combination with cytological examination. The kit can be used for qualitative detection of high-risk human papilloma viruses in cervical cell samples of patients, and typing identification of HPV16 and HPV18 types is realized while HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 are detected. The kit is used for qualitatively detecting high-risk HPV DNA in cervical cells of a patient and determining whether the patient needs colposcope examination or not.

The invention relates to the technical fields of genetic engineering and medical detection, and provides a methylated EphA7 nucleotide fragment as a specific diagnosis marker of cervical cancer, and aprimer set, a probe and a reagent kit relevant with the methylated EphA7 nucleotide fragment, and an application of the methylated EphA7 nucleotide fragment to preparation of a cervical cancer screening and diagnosing preparation. The inventor finds that the methylation degree of a promoter region of EphA7 genes in cervical tissues is in significant correlation with the generation of the cervicalcancer, and the methylated EphA7 nucleotide fragment can be used as a biology marker for assisting in diagnosis of the cervical cancer, so that the human cervical cancer can be timely screened and diagnosed for early stage, and the waste of medical resources is avoided.

The invention discloses application of prescriptions composed of vitamin C and baicalein in cervical cancer treatment. A plurality dosages of baicalein and vitamin C form different prescriptions, and the prescriptions are compared with corresponding dosage of single baicalein and single vitamin C and act on U14 cervical cancer tumor-bearing mouse models and HeLa cells. Animal experiments show that the prescriptions composed of the vitamin C and the baicalein are better in tumor inhibiting effect and smaller in toxic and side effects as compared with single vitamin C and single baicalein. Cell experiment results show that when same medicine dosage acts on cells for 12 hours, the cells in prescription groups start to atrophy and deform, and the number of cells is reduced; when the same medicine dosage acts on the cells for 36 hours, cell structures disappear, most cells die, and the inhibiting effect of the prescription groups is evidently better than that of the single vitamin C and single baicalein groups. Therefore, the prescriptions composed of the vitamin C and the baicalein is applicable to cervical cancer treatment.

The invention discloses an active learning-based cervical cancer identification model training method. The method comprises the following steps of preparing multiple cervical cancer section digital images, constructing a sample library, and training an identification model by adopting the cervical cancer section digital images in the sample library; for the cervical cancer section digital images in the sample library, outputting corresponding identification results through identification of the identification model, wherein the identification results comprise cells difficultly identified by the identification model; and in the identification results, tagging the difficultly identified cells in a manual tagging mode, updating the tagged cervical cancer digital images to the sample library,and re-training the identification model for performing identification, until the difficultly identified cells do not exist in all the identification results. Compared with the prior art, the method has the beneficial effects of high identification speed, high identification precision and capability of automatically filtering a large amount of cervical cancer cells with remarkable features.